Despite the prominent progress in understanding cancer immunosurveillance mechanisms, there are some types of problems which have been identified to hinder effective and successful immunotherapy of cancers. Such problems have been ascribed to the tumor abilities in the creation of a tolerant milieu that can impair immune responses against cancer cells. In the present study, we represent possible approaches for metabolic reprogramming of T cells in cancer immunotherapy to overcome tumor metabolic impositions on immune responses against cancer cells. Metabolic suppression of effector immune cells in tumor milieu is one of the important strategies recruited by tumor cells to escape from immunogenic cell death. We have investigated the metabolic reprogramming of T cells as a method and a possible new target for cancer immunotherapy. Synergic effects of PPAR ligands in immunotherapy of cancers on the metabolic reprogramming of T cells have been noticed by several studies as a new target of cancer immunotherapy. The current wealth of data like this promises a future scenario which the consideration of metabolic restriction in the tumor microenvironment and administration of therapeutic agents such as PPAR ligands to overcome metabolic restrictions on T cells (refreshing their functionality) may be effective and enhance the accountability and efficacy of cancer immunotherapy.

中文翻译：

---

靶向PPAR配体是癌症免疫疗法中T细胞代谢重编程的可能方法。

尽管在理解癌症免疫监视机制方面取得了显着进展，但已发现某些类型的问题阻碍了癌症的有效免疫治疗。此类问题已归因于创建可损害针对癌细胞的免疫反应的耐受环境中的肿瘤能力。在本研究中，我们代表了癌症免疫疗法中T细胞代谢重编程的可能方法，以克服肿瘤对免疫反应的强加于癌细胞的免疫反应。肿瘤环境中效应免疫细胞的代谢抑制是肿瘤细胞从免疫原性细胞死亡中逃脱的重要策略之一。我们已经研究了T细胞代谢重编程作为一种方法和可能的癌症免疫治疗新靶标。PPAR配体在癌症免疫治疗中对T细胞代谢重编程的协同作用已被多项研究视为癌症免疫治疗的新目标。像这样的当前大量​​数据预示着未来的发展前景，即在肿瘤微环境中考虑代谢限制以及治疗药物（例如PPAR配体）以克服对T细胞的代谢限制（刷新其功能）可能是有效的，并增强了责任感和癌症免疫疗法的功效。